Supplementary tables:

Supplementary Table 1: Correlation between key clinical parameters and histopathologic findings in idiopathic membranous nephropathy

|  |  |  |
| --- | --- | --- |
|  | univariate analysis | multivariate analysis |
|  | odds ratio (95% CI) | P – value | odds ratio (95% CI) | P - value |
| eGFR<60 ml/min % global sclerosis % segmental sclerosis % global/segmental sclerosis interstitial inflammation tubular atrophy/interstitial fibrosis arteriosclerosis % foot process effacement stage of disease | 1.04 (1.01-1.07)1.05 (1.01-1.10)1.04 (1.02-1.06)2.92 (1.71-4.98)4.91 (2.61-9.22)2.34 (1.44-3.80)1.05 (0.98-1.13)2.99 (1.55-5.77) | 0.0030.02<0.001<0.001<0.0010.0010.10.001 | 1.04 (0.96-1.12)1.01 (0.95-1.09) excluded0.61 (0.19-1.98)5.35 (1.70-16.89)1.28 (0.58-2.84)1.11 (0.96-1.28)4.242 (0.92-19.60) | 0.430.70.40.0040.60.20.06 |
| serum albumin < 2.0g/dL % global sclerosis % segmental sclerosis % global/segmental sclerosis interstitial inflammation tubular atrophy/interstitial fibrosis arteriosclerosis % foot process effacement stage of disease | 0.95 (0.89-1.01)1.01 (0.97-1.05)0.98 (0.95-1.01)1.31 (0.77-2.21)0.67 (0.42-1.08)0.74 (0.48-1.15)1.11 (1.00-1.23)0.50 (0.23-1.10) | 0.090.70.20.30.10.20.050.08 | 0.97 (0.89-1.05)1.02 (0.96-1.08)excluded3.82 (1.42-10.26)0.65 (0.26-1.61)0.62 (0.33-1.17)1.17 (1.00-1.37)0.19 (0.04-0.91) | 0.40.60.0080.30.10.060.04 |
| proteinuria >3 g % global sclerosis % segmental sclerosis % global/segmental sclerosis interstitial inflammation tubular atrophy/interstitial fibrosis arteriosclerosis % foot process effacement stage of disease | 1.01 (0.98-1.04)1 (0.95-1.05)1 (0.98-1.03)1.06 (0.59-1.91)1.57 (0.92-2.70)1.18 (0.72-1.94)1.02 (0.98-1.06)0.75 (0.35-1060) | 0.70.80.80.80.10.50.30.5 | 0.96 (0.90-1.03)1.01 (0.95-1.07)excluded0.58 (0.14-1.42)3.11 (1.20-8.06)0.92 (0.49-1.73)1.03 (0.98-1.09)0.44 (0.15-1.30) | 0.20.70.20.020.80.20.1 |
| proteinuria >10 g % global sclerosis % segmental sclerosis % global/segmental sclerosis interstitial inflammation tubular atrophy/interstitial fibrosis arteriosclerosis % foot process effacement stage of disease | 1 (0.98-1.02)1.03 (0.99-1.07)1 (0.99-1.02)1.74 (1.10-2.75)1.21 (0.86-1.62)1.13 (0.78-1.62)1.04 (0.99-1.10)1.06 (0.61-1.84) | 0.750.20.90.0190.2790.520.130.842 | 0.97 (0.92-1.02)1.02 (0.97-1.08)excluded1.58 (0.79-3.18)1.22 (0.64-2.13)1.02 (0.63-1.65)1.04 (0.97-1.11)1.05 (0.42-2.62) | 0.20.40.20.50.90.30.9 |
| Hypertension % global sclerosis % segmental sclerosis % global/segmental sclerosis interstitial inflammation tubular atrophy/interstitial fibrosis arteriosclerosis % foot process effacement stage of disease | 1.05 (1.01-1.09)1.01 (0.97-1.05)1.03 (1.00-1.05)1.35 (0.86-2.13)1.18 (1.19-2.69)1.15 (0.80-1.66)1.03 (0.99-1.06)1.93 (1.04-3.58) | 0.0280.7790.0370.1930.0060.4420.1620.037 | excludedexcluded1.01 (0.99-1.04)excluded1.58 (0.92-2.73)0.92 (0.59-1.43)excluded 1.71 (0.79-3.71) | 0.30.10.70.2 |
| Smoking % global sclerosis % segmental sclerosis % global/segmental sclerosis interstitial inflammation tubular atrophy/interstitial fibrosis arteriosclerosis % foot process effacement stage of disease  | 1.02 (0.99-1.04)1.01 (0.97-1.05)1.01 (0.99-1.03)1.46 (0.85-2.52)1.92 (1.20-3.08)1.94 (1.20-3.15)1.02 (0.97-1.06)0.91 (0.47-1.76) | 0.1930.6320.1780.170.0070.0070.4720.782 | 1.07 (0.98-1.17)1 (0.94-1.06)excluded1.53 (0.61-3.83)1.77 (0.77-4.03)1.8 (0.97-3.32)1.02 (0.96-1.08)0.76 (0.25-2.37) | 0.11.00.40.20.060.60.8 |

\* variables were excluded based on conditional entry of the variable by the likelihood ratio

Supplementary Table 2: Treatment utilization in the study population

|  |  |  |
| --- | --- | --- |
| **treatment**  | N | % |
| ACEi/ARBs  | 108 | 84 |
| Statin | 90 | 78 |
| immunosuppressants  steroids  cyclophosphamide  mycophenolate mofetil  cyclosporine  tacrolimus  rituximab  | 98793249621016 | 7460243747812 |